MedTrace Logo

Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock

NCT04611607 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 303

Last updated 2022-07-27

No results posted yet for this study

Summary

This registry will provide information about the efficacy and safety of cangrelor in a very high-risk group of patients with acute myocardial infarction undergoing PCI. It will not only include patients with cardiogenic shock, but a variety of patients not able to swallow tablets, such as those after CPR and/or with invasive or non-invasive ventilation. Therefore it will provide information about the use of cangrelor beyond the current knowledge.

Conditions

  • Acute Myocardial Infarction

Sponsors & Collaborators

  • Ferrer Internacional S.A.

    collaborator INDUSTRY

  • IHF GmbH - Institut für Herzinfarktforschung

    lead OTHER

Principal Investigators

  • Uwe Zeymer, Prof · Klinikum Ludwigshafen ; Stiftung IHF Institut für Herzinfarktforschung

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2022-06-07
Completion
2022-06-07

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04611607 on ClinicalTrials.gov